ESR1 and breast cancer: A somewhat conflicting pre-clinical model to that of Toth-Fejel and colleagues noted in the MCF-7 cell line that overexpression of AR made ERα-positive breast cancer cells resistant to the inhibitory effects of tamoxifen in xenograft and nude mice studies, and that treatment with anti-androgen therapy could overcome this resistance [59].